Core Viewpoint - The conference highlighted the innovative application of the theory of "Luo Disease" in the diagnosis and treatment of prostate diseases, particularly focusing on the clinical research progress of the innovative Chinese medicine Xia Li Qi capsules, providing new solutions for the health of middle-aged and elderly men [1][3]. Group 1: Prostate Disease Insights - Prostate hyperplasia is the most common benign disease causing lower urinary tract symptoms in elderly men, with an incidence rate exceeding 50% in men over 60 years old and reaching 83% by age 80 [3]. - Traditional Chinese medicine categorizes prostate hyperplasia as "Luo Bi," primarily caused by "kidney deficiency and bladder dysfunction" [3]. Group 2: Xia Li Qi Capsules - Xia Li Qi capsules are developed based on the theory of Luo Disease, featuring a formulation that combines various herbs to create a treatment system that addresses both symptoms and root causes [4]. - Clinical studies have shown that Xia Li Qi capsules significantly reduce the International Prostate Symptom Score (IPSS), improve symptoms like urinary urgency and frequency, and effectively inhibit prostate enlargement [4]. Group 3: Clinical Guidelines and Future Directions - Xia Li Qi capsules have been included in multiple authoritative guidelines and consensus documents related to the management of benign prostate hyperplasia, establishing them as a preferred option for integrated treatment [5]. - The current treatment landscape for prostate hyperplasia faces challenges with symptom management, necessitating the exploration of traditional Chinese medicine's holistic approach for better disease management [5].

Group 1: Company Performance - In Q1 2025, the company achieved a revenue of 2.358 billion yuan, a year-on-year decline of 6.52% [5] - The net profit attributable to shareholders was 326 million yuan, an increase of 7.25% year-on-year [10] - The operating cash flow reached 340 million yuan, showing a significant increase of 190.67% [5] Group 2: R&D and Innovation - The company has maintained a continuous increase in R&D investment, having launched 5 innovative traditional Chinese medicines in the past four years [10] - Currently, there are 17 innovative patented traditional Chinese medicines covering seven major disease areas [3] - The company is focusing on enhancing its core technological innovation capabilities and optimizing its marketing system to maintain stable product gross margins [9] Group 3: Market Strategy - The company plans to expand the market for its core product, Lianhua Qingwen, by exploring new application scenarios and implementing a comprehensive brand marketing strategy [6] - Lianhua Qingwen has obtained approvals in over 30 countries and regions, with efforts to enhance its brand influence overseas [6] - Future product development will focus on respiratory, endocrine, digestive, gynecological, and pediatric diseases [6] Group 4: Policy and Industry Outlook - The Chinese government is promoting the development of traditional Chinese medicine (TCM) through various policies, including the "14th Five-Year Plan for TCM Development" [8] - The government has emphasized the importance of TCM in disease prevention, treatment, and health maintenance, which is expected to drive industry growth [7] - The overall policy environment is favorable for the high-quality development of the TCM industry, supporting innovation and structural optimization [8] Group 5: Investor Relations and Value Management - The company aims to align market value with intrinsic value through transparent information disclosure and effective investor relations management [9] - A stable and high-quality investor base is being established to maximize overall company benefits and shareholder wealth [9] - The company has a structured plan for sustainable and scientific returns to investors, considering multiple factors such as operational conditions and development goals [2]

Group 1 - The core initiative of Yiling Pharmaceutical is to promote the "Quality China" construction and high-quality development by enhancing brand recognition and storytelling for Chinese brands, particularly in the context of the upcoming "China Brand Day" in 2025 [3] - Yiling Pharmaceutical has launched the "5·10 Yiling Brand Month" series of activities in collaboration with nearly a hundred well-known chain pharmacies across the country, focusing on the theme "Technology Empowers Health, Brand Leads the Future" [3][4] - The activities will include public welfare science popularization, chronic disease management, and digital services to improve public health literacy and contribute positively to the construction of a healthy China [3][4] Group 2 - During the "5·10 Yiling Brand Month," Yiling Pharmaceutical will integrate quality medical resources through a multi-dimensional approach, including online science popularization and offline services, to provide comprehensive health service experiences for consumers [4] - The initiative will involve expert online live broadcasts and offline health screenings and consultations for chronic diseases, promoting the concept of "early screening, early diagnosis, early intervention" [4] - Yiling Pharmaceutical will collaborate with well-known chain pharmacies to conduct public health science roadshows across the country, aiming to enhance public access to health knowledge and services [4] Group 3 - Yiling Pharmaceutical has established a unique technological core competitiveness through the systematic construction of the theory of collateral diseases, which has led to significant technological innovations and the completion of multiple major projects [5][6] - The company has received six national science and technology awards and has developed patented new drugs for prevalent and major diseases, gaining recognition from clinical experts and patients [6] - Yiling's products, such as Lianhua Qingwen capsules and Tongxinluo capsules, have been approved for sale in over 50 countries and regions, showcasing the global reach of traditional Chinese medicine [6] Group 4 - As a national key high-tech enterprise, Yiling Pharmaceutical adheres to the principle of "inheritance and innovation for the benefit of humanity," actively engaging in social responsibility initiatives [7] - The company has achieved a water resource reuse rate of 97% through clean production and low-carbon energy practices, contributing to green development [7] - Yiling Pharmaceutical has created over 60 high-standard Chinese medicinal herb bases across more than 20 provinces, providing numerous job opportunities and revitalizing rural industries [7]

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].